Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2026
Principal Office: Rockville, Maryland
Context: The filing discloses regulatory authorization to initiate a new clinical trial for the Company's lead asset, zabilugene almadenorepvec (VCN-01).
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Developments
- Regulatory Authorization: The Spanish Agency of Medicines and Medical Devices (AEMPS) authorized the initiation of the VIRAGE2 clinical trial.
- Trial Design: VIRAGE2 is a Phase IIa, single-arm, single-center, open-label, proof-of-concept trial.
- Objective: To evaluate increased frequency dosing of VCN-01 (at least 3 doses given 2 months apart) in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) for newly-diagnosed metastatic pancreatic cancer.
- Historical Context: The trial builds on the 112-patient VIRAGE Phase 2b trial, where patients receiving 2 doses of VCN-01 (3 months apart) showed significantly improved overall survival, progression-free survival, and duration of response compared to single-dose or chemotherapy-only groups.
- Regulatory Feedback: Both the EMA and FDA previously recognized the survival benefits of the 2-dose regimen and suggested investigating more frequent repeated dosing.
Outlook, Risks, and Management Commentary
- Strategic Goal: Results from VIRAGE2 will inform the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial.
- Forward-Looking Statements: The press release furnished with this filing contains "safe harbor" language indicating that certain statements are forward-looking rather than historical.
- Risk Disclosure: The filing notes that the information in Item 7.01 and the press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the specific inclusion/exclusion criteria for the VIRAGE2 trial to understand patient eligibility.
- Monitor the timeline for patient enrollment and the expected date for preliminary data readout.
- Review the Company's cash runway and capital requirements to fund the VIRAGE2 trial and potential future Phase 3 studies.
- Confirm if the FDA has granted similar authorization for a comparable trial in the United States.